Status:
COMPLETED
Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer
Lead Sponsor:
Yale University
Collaborating Sponsors:
Massachusetts General Hospital
Women and Infants Hospital of Rhode Island
Conditions:
Menopause
Eligibility:
FEMALE
40+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effects of a personalized menopausal therapy risk assessment and genetic counseling intervention on knowledge, risk perception, and decision-making in hea...
Detailed Description
Women with a family history of breast cancer have several menopausal therapy options, including tamoxifen, hormone therapy, alternative medications, or no treatment. This complex decision should be ba...
Eligibility Criteria
Inclusion
- at least one first degree relative with breast cancer
- age 40 or older
Exclusion
- currently taking a menopausal therapy
- previous cancer diagnosis (except basal cell carcinoma)
- previous diagnosis of atypical hyperplasia
- previous diagnosis of lobular carcinoma in situ (LCIS)
- known carrier of a BRCA1 or BRCA2 mutation
- personal history of heart disease
- \>10% risk of carrying a BRCA1 or BRCA2 mutation
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
End Date :
March 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00349011
Start Date
August 1 2002
End Date
March 1 2004
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Cancer Genetic Counseling, Yale Cancer Center, Yale University School of Medicine
New Haven, Connecticut, United States, 06510